Envoy Medical (COCH) Long-Term Deferred Tax (2022 - 2023)

Envoy Medical's (COCH) quarterly Long-Term Deferred Tax came in at $50.2 million in Q4 2023, up 13.08% year-on-year from $44.4 million in Q4 2022, and up 13.08% quarter-over-quarter from $44.4 million in Q4 2022.

Envoy Medical (COCH) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends

Envoy Medical has disclosed Long-Term Deferred Tax across 2 years of filings, most recently posting $50.2 million for Q4 2023.

  • Long-Term Deferred Tax for Q4 2023 came in at $50.2 million, up 13.08% year-over-year; the trailing twelve-month figure through Dec 2023 was $50.2 million (up 13.08% YoY), and the FY2023 annual result was $50.2 million, up 13.08% from the prior year.
  • Long-Term Deferred Tax came in at $50.2 million for Q4 2023 at Envoy Medical, up from $44.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $50.2 million in Q4 2023 to a low of $44.4 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn
10 Envoy Medical 44.81 Mn 19.56 Mn -274,000.00

Historic Data

Download Data
DateValue
Dec 31, 2023 50.23 Mn
Dec 31, 2022 44.42 Mn